Thursday, February 01, 2024 12:15:03 PM
IMHO, their best bet is to continue to 'talk about' it and secure interest from someone with pockets deep enough to fully take it to market. I believe that SHMN will focus on small scale product development around ABBIE, not as a revenue source, but as proof of concept. If they can show that there are beneficial uses of the technology with only meager investment, it makes the IP more attractive to a potential licensee with enough resources to more fully develop it.
This approach is a win/win. SHMN reaps significant ROI for their initial investment in ABBIE through licensing fees without assuming the risk and expense of bringing it to market themselves. The Licensee realizes significant margins through their commercial activities in exchange for assumption of the above risk/expense, but did not have to expend the time/capital associated with its initial development.
Again, all of the above is rampant speculation and a projection of how I would approach the asset (given what little we know about it at this point).
Recent SHMN News
- Gene Editing Company Joins Forces to Advance Gene Therapy • AllPennyStocks.com • 04/01/2024 03:46:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM